Journal of Law, Medicine and Ethics 30 (3):381-389 (2002)

Authors
Abstract
Clinical gene transfer research has both a unique history and a complex and layered system of research oversight, featuring a unique review body, the Recombinant DNA Advisory Committee. This paper briefly describes the process of decision-making about clinical GTR, considers whether the questions, problems, and issues raised in clinical GTR are unique, and concludes by examining whether the RAC's oversight is a useful model that should be reproduced for other similar areas of clinical research.Clinical GTR is governed by the same oversight system as most clinical trials, with a significant addition: the RAC. Like other research with human subjects, GTR, if it is affiliated with a federally funded institution, must be approved by an institutional review board whose activities are governed by the common rule, that is, the federal regulations for protection of human subjects in research. Like other research intended to produce a drug, device, or biologic to be marketed in the United States, GTR is also overseen by the Food and Drug Administration.
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1111/j.1748-720X.2002.tb00407.x
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 58,348
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Defining and Describing Benefit Appropriately in Clinical Trials.Nancy M. P. King - 2000 - Journal of Law, Medicine and Ethics 28 (4):332-343.
Phase I Cancer Trials: A Collusion of Misunderstanding.Matthew Miller - 2000 - Hastings Center Report 30 (4):34-43.

View all 6 references / Add more references

Citations of this work BETA

The Diverse Ethics of Translational Research.Neema Sofaer & Nir Eyal - 2010 - American Journal of Bioethics 10 (8):19-30.
Gene Therapy Oversight: Lessons for Nanobiotechnology.Susan M. Wolf, Rishi Gupta & Peter Kohlhepp - 2009 - Journal of Law, Medicine and Ethics 37 (4):659-684.
Valuing Risk: The Ethical Review of Clinical Trial Safety.Jonathan Kimmelman - 2004 - Kennedy Institute of Ethics Journal 14 (4):369-393.

View all 15 citations / Add more citations

Similar books and articles

The Oversight of Human Gene Transfer Research.LeRoy Walters - 2000 - Kennedy Institute of Ethics Journal 10 (2):171-174.
Revolution or Reform in Human Subjects Research Oversight.Steven Joffe - 2012 - Journal of Law, Medicine and Ethics 40 (4):922-929.
Reflections on Governance Models for the Clinical Translation of Stem Cells.Jeremy Sugarman - 2010 - Journal of Law, Medicine and Ethics 38 (2):251-256.
Can Enhancement Be Distinguished From Prevention in Genetic Medicine?Eric T. Juengst - 1997 - Journal of Medicine and Philosophy 22 (2):125-142.
Are All Genes Regulatory Genes?Rosario Michael Piro - 2011 - Biology and Philosophy 26 (4):595-602.
The US Model for Oversight of Human Stem Cell Research.Lindsay Parham & Bernard Lo - 2010 - In John Elliott, W. Calvin Ho & Sylvia S. N. Lim (eds.), Bioethics in Singapore: The Ethical Microcosm. World Scientific. pp. 109.

Analytics

Added to PP index
2010-08-31

Total views
26 ( #404,567 of 2,419,966 )

Recent downloads (6 months)
2 ( #351,148 of 2,419,966 )

How can I increase my downloads?

Downloads

My notes